Mathematical model of the antibody response to hepatitis B vaccines: Implications for reduced schedules

Vaccine

Volumn 25, Issue 18, 2007, Pages 3705-3712

  Wilson, Jamie N ^a   Nokes, D James ^b   Medley, Graham F ^a   Shouval, Daniel ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Hepatitis B vaccines; Mathematical model; Memory

Indexed keywords

HBVAX 1; HEBERBIOVAC; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HEPATITIS B; HUMAN; IMMUNOLOGICAL MEMORY; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL;

HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOLOGIC MEMORY; MODELS, BIOLOGICAL;

EID: 34147171716     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.012     Document Type: Article

References (30)

1. Shouval D. Hepatitis B vaccines. J Hepatol 39 Suppl. 1 (2003) S70-S76
2. Wilson J.N., Nokes D.J., and Dimmock N.J. Analysis of the relationship between immunogenicity and immunity for viral subunit vaccines. J Med Virol 64 4 (Aug 2001) 560-568
3. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 355 9203 (2000) 561-565
4. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 11 (1996) 1019-1027
5. Wistrom J., Ahlm C., Lundberg S., Settergren B., and Tarnvik A. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 17 17 (1999) 2162-2165
6. Wilson J.N., and Nokes D.J. Do we need 3 doses of hepatitis B vaccine?. Vaccine 17 20-21 (1999) 2667-2673
7. Gesemann M., and Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 13 5 (1995) 443-447
8. Scheiermann N., Gesemann M., Maurer C., Just M., and Berger R. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine 8 6 (1990) 60-62
9. Whittle H.C., Maine N., Pilkington J., Mendy M., Fortuin M., Bunn J., et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 345 8957 (1995) 1089-1092
10. Wheeley S.M., Boxall E.H., Tarlow M.J., Gatrad A.R., Anderson J., Bissenden J., et al. Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: final report on a West Midlands pilot study. J Med Virol 30 2 (1990) 113-116
11. Yuen M.F., Lim W.L., Cheng C.C., Lam S.K., and Lai C.L. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 29 3 (Mar 1999) 924-927
12. Lee P.I., Lee C.Y., Huang L.M., and Chang M.H. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 126 5 Pt 1 (1995) 716-721
13. McDermott A.B., Madrigal J.A., Sabin C.A., Zuckerman J.N., and Cohen S.B. The influence of host factors and immunogenetics on lymphocyte responses to Hepagene vaccination. Vaccine 17 11-12 (1999) 1329-1337
14. Abraham P., Mistry F.P., Bapat M.R., Sharma G., Reddy G.R., Prasad K.S., et al. Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine 17 9-10 (1999) 1125-1129
15. Surya I.G.P., Kishimoto K., Sudaryat S., Tsuda F., Hamid A., Takahashi K., et al. Prevention of mother-to-infant transmission of hepatitis B virus with use of a preS2-containing vaccine in Bali Indonesia. Vaccine Res 5 4 (1996) 203-213
16. Lugoboni F., Migliozzi S., Schiesari F., Pauletto N., Bovo G.L., Ciaffoni S., et al. Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine 15 9 (1997) 1014-1016
17. Trivello R., Chiaramonte M., Ngatchu T., Baldo V., Majori S., Moschen M.E., et al. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine 13 2 (1995) 139-141
18. Leroux-Roels G., Desombere I., De Tollenaere G., Petit M.A., Desmons P., Hauser P., et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults. Vaccine 15 16 (1997) 1724-1731
19. Heineman T.C., Clements-Mann M.L., Poland G.A., Jacobson R.M., Izu A.E., Sakamoto D., et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17 22 (1999) 2769-2778
20. Marsano L.S., West D.J., Chan I., Hesley T.M., Cox J., Hackworth V., et al. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 16 6 (1998) 624-629
21. Hourvitz A., Mosseri R., Solomon A., Yehezkelli Y., Atsmon J., Danon Y.L., et al. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J Viral Hepat 3 1 (1996) 37-42
22. Gonzalez-Griego Mde J., Cinza Z., Ortega A., Gali M.M., Santoyo M.E., Garcia G., et al. A comparative study between different regimens for administering 2 doses of the Cuban anti-hepatitis B vaccine. Rev Cubana Med Trop 50 3 (1998) 218-220
23. Shapira M.Y., Zeira E., Adler R., and Shouval D. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 34 1 (2001) 123-127
24. Nelder J.A., and Mead R. A simplex method for function minimization. Comput J 7 4 (1965) 308-313
25. Bernstein S.R., Krieger P., Puppala B.L., and Costello M. Incidence and duration of hepatitis B surface antigenemia after neonatal hepatitis B immunization. J Pediatr 125 4 (1994) 621-622
26. Lai C.L., Wong B.C., Yeoh E.K., Lim W.L., Chang W.K., and Lin H.J. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology 18 4 (1993) 763-767
27. Tabor E., Gerety R.J., Cairns J., and Bayley A.C. Antibody responses of adults, adolescents, and children to a plasma-derived hepatitis B vaccine in a rural African setting. J Med Virol 32 2 (1990) 134-138
28. Tabor E., Cairns J., Gerety R.J., and Bayley A.C. Nine-year follow-up study of a plasma-derived hepatitis B vaccine in a rural African setting. J Med Virol 40 3 (1993) 204-209
29. Da Villa G., Pelliccia M.G., Peluso F., Ricciardi E., and Sepe A. Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res Virol 148 2 (1997) 109-114
30. Van der Sande M.A.B., Mendy M., Waight P., Doherty C., McConkey S.J., Hall A.J., et al. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 25 8 (2007) 1509-1512